dougall advisors: Live & Latest News Updates : Vimarsana.com

CHARM Therapeutics Bolsters Leadership Team with Key Promotion and Strategic Appointment

SpyBiotech Announces First Patient Dosed in Phase I Trial of SPYVLP01

Hummingbird Diagnostics GmbH to Unveil Pioneering Alzheimer's Disease Biomarker Research at CTAD Conference

SpyBiotech Announces MHRA Clinical Trial Application Filing for SPYVLP01

Trueline Therapeutics Inc.: Trueline Therapeutics Announces Completion of IND-Enabling Studies for MCL1 Inhibitor TTX-810

- TTX-810 is designed for rapid clearance to circumvent mechanism-based risks of MCL1 inhibition - High potency affords robust anti-tumor effects whilst preserving cardiomyocyte viability - Trueline

Numab Therapeutics AG: Numab Therapeutics Announces First Subject Dosed in Phase 1 Clinical Study of NM26 Program

NM26-2198 is a first-in-class bi-specific antibody designed to simultaneously block multiple targets for the treatment of moderate to severe atopic dermatitis (AD) Combined single ascending dose

Empyrean Neuroscience, Inc.: Empyrean Neuroscience Launches with $22M Series A and Genetic Engineering Platform to Advance Pipeline of Neuroactive Compounds Targeting CNS Disorders

- Founded on the first and only platform designed to genetically engineer small molecule therapeutics from fungi and plants - - Led by veteran biotech executives Usman Azam, Chief Executive Officer

SpyBiotech Appoints Seasoned Biotech Executive Mark Leuchtenberger as Chief Executive Officer

Novel Vaccine Company Expands Leadership Team and Establishes US Presence SpyBiotech, a British biotechnology company with a novel vaccine platform technology that can target infectious diseases,

Hummingbird Diagnostics GmbH: Hummingbird Diagnostics Publishes Study of miRisk as a Predictor of Immunotherapy Efficacy in Advanced-Stage NSCLC

Proprietary microRNA signature (miRisk) may support immunotherapy treatment decisions as a blood-based complementary diagnostic Results published in Journal of Thoracic Oncology Clinical and Research

Numab Therapeutics AG: Numab Therapeutics and Ono Pharmaceutical Enter Development and License Agreement for Multispecific Antibody Candidate Involving Novel Immuno-Oncology Target

Numab Therapeutics AG ("Numab") and Ono Pharmaceutical Co., Ltd. ("Ono") today announced that Ono has exercised its option to enter into a development and license agreement for a multispecific antibody